Dexrazoxane

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 818 publications

Erratum: Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2.

Erratum: Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 24, 2026

Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2.

Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 06, 2026

A bidirectional pyroptosis regulation strategy to resolve cardiotoxicity-antitumor efficacy dilemma of doxorubicin.

A bidirectional pyroptosis regulation strategy to resolve cardiotoxicity-antitumor efficacy dilemma of doxorubicin.

Journal: Nanoscale

Published: August 04, 2026

Intravenous dexrazoxane for haemorrhagic myocardial infarction: the SHIELD-MI study.

Intravenous dexrazoxane for haemorrhagic myocardial infarction: the SHIELD-MI study.

Journal: European heart journal

Published: July 17, 2026

Dexrazoxane in children receiving anthracyclines: efficacy, safety, and region-specific considerations for Latin America.

Dexrazoxane in children receiving anthracyclines: efficacy, safety, and region-specific considerations for Latin America.

Journal: Cardiology in the young

Published: June 30, 2026

Ferroptosis in Anthracycline Cardiotoxicity: Mechanisms, the Cardioprotection Paradox and the Limits of Single-Pathway Thinking.

Ferroptosis in Anthracycline Cardiotoxicity: Mechanisms, the Cardioprotection Paradox and the Limits of Single-Pathway Thinking.

Journal: Journal of applied toxicology : JAT

Published: June 25, 2026

Dexrazoxane for Cardioprotection During Anthracycline Therapy: A Systematic Review and Meta-Analysis.

Dexrazoxane for Cardioprotection During Anthracycline Therapy: A Systematic Review and Meta-Analysis.

Journal: The Canadian journal of cardiology

Published: May 12, 2026

Cardiotoxicity, survival, and dexrazoxane use in patients with soft tissue sarcoma: a Danish population‑based cohort study.

Cardiotoxicity, survival, and dexrazoxane use in patients with soft tissue sarcoma: a Danish population‑based cohort study.

Journal: Acta oncologica (Stockholm, Sweden)

Published: April 11, 2026

Analysis of gene expression changes upon topobexin treatment and TOP2B-knockout in hiPSC derived cardiomyocytes.

Analysis of gene expression changes upon topobexin treatment and TOP2B-knockout in hiPSC derived cardiomyocytes.

Journal: Biology open

Published: March 28, 2026

Integrated Multi-omics Reveals CDKN1A Suppression and Metabolic Regulation as Key Mechanisms of Huangqi Guizhi Wuwu Decoction Against Doxorubicin-Induced Cardiotoxicity.

Integrated Multi-omics Reveals CDKN1A Suppression and Metabolic Regulation as Key Mechanisms of Huangqi Guizhi Wuwu Decoction Against Doxorubicin-Induced Cardiotoxicity.

Journal: Cardiovascular toxicology

Published: March 15, 2026

Effects of anthracyclines on arteriosclerosis and the protective effect of dexrazoxane in breast cancer patients.

Effects of anthracyclines on arteriosclerosis and the protective effect of dexrazoxane in breast cancer patients.

Journal: Journal of chemotherapy (Florence, Italy)

Published: March 13, 2026

Heart transplantation in pediatric oncology patients.

Heart transplantation in pediatric oncology patients.

Journal: JHLT open

Published: March 11, 2026

Showing 1-12 of 818

Last Updated: 09/26/2026